Study of Changes and Characteristics of Genes in Patients With Pancreatic Cancer for Better Treatment Selection

Exclusion Criteria

• •Patient must have a tumor lesion that is amenable to a core needle biopsy.
• •Patients must have a measurable lesion by RECIST 1.1 in addition to the lesion that is going to be biopsied.
• •Patients must be fit enough to safely undergo a tumor biopsy.
• •Age 18 years or older.
• •Eastern Cooperative Group (ECOG) performance status of 1 or less.
• •Life expectancy of greater than 90 days.
• •Patients must have normal organ and marrow function
• •Patients must undergo systemic treatment with m-FOLFIRINOX or nab-paclitaxel as a first line standard systemic palliative treatment or combination treatment with m-FOLFIRINOX or nab-paclitaxel with or without other investigational agents within a clinical trial as a first line palliative treatment.
• •Ability to understand and willing to sign a written informed consent document.
• •Patients with one or more contraindications to tumor biopsy.
• •Patients who have prior systemic treatment (chemotherapy or any other anti-cancer agent) in advanced setting.
• •Patients who are currently on anti-cancer treatment including chemotherapy.
• •Patients with known brain metastases.
• •Patients with advanced PDAC who are going to be treated with gemcitabine monotherapy in advanced setting.
• •Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• •Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures.